SOURCE: Dynavax Technologies

Dynavax Technologies

January 12, 2015 16:05 ET

Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

BERKELEY, CA--(Marketwired - Jan 12, 2015) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

Eddie Gray, Chief Executive Officer of Dynavax, will provide a company overview and update. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit

Contact Information

  • Contact:
    Michael Ostrach
    Chief Business and Principal Financial Officer
    Email Contact